AIDS and Behavior

, Volume 18, Issue 12, pp 2409–2422 | Cite as

ACT2 Peer-Driven Intervention Increases Enrollment into HIV/AIDS Medical Studies Among African Americans/Blacks and Hispanics: A Cluster Randomized Controlled Trial

  • Marya Gwadz
  • Charles M. Cleland
  • Mindy Belkin
  • Amanda Ritchie
  • Noelle Leonard
  • Marion Riedel
  • Angela Banfield
  • Pablo Colon
  • Vanessa Elharrar
  • Jonathan Kagan
  • Donna Mildvan
  • ACT2 Collaborative Research Team
Original Paper

Abstract

African American/Black and Hispanic persons living with HIV/AIDS (“AABH-PLHA”) are under-represented in HIV/AIDS medical studies (HAMS). This paper evaluates the efficacy of a social/behavioral intervention to increase rates of screening for and enrollment into HAMS in these populations. Participants (N = 540) were enrolled into a cluster randomized controlled trial of an intervention designed to overcome multi-level barriers to HAMS. Primary endpoints were rates of screening for and enrollment into therapeutic/treatment-oriented and observational studies. Intervention arm participants were 30 times more likely to be screened than controls (49.3 % vs. 3.7 %; p < .001). Half (55.5 %) of those screened were eligible for HAMS, primarily observational studies. Nine out of ten found eligible enrolled (91.7 %), almost all into observational studies (95.2 %), compared to no enrollments among controls. Achieving appropriate representation of AABH-PLHA in HAMS necessitates modification of study inclusion criteria to increase the proportion found eligible for therapeutic HAMS, in addition to social/behavioral interventions.

Keywords

Clinical trials HIV/AIDS African American Black Hispanic Minority Motivational Interviewing Health care disparities 

References

  1. 1.
    Castillo-Mancilla J, Cohn S, Krishnan S, et al. Minorities remain underrepresented in HIV/AIDS research despite access to clinical trials. HIV Clin Trials. 2014;15(1):14–26.PubMedCrossRefGoogle Scholar
  2. 2.
    National Institute of Allergy and Infectious Diseases [NIAID]. HIV infection in minority populations 2008. http://www.niaid.nih.gov/topics/HIVAIDS/Understanding/PopulationSpecificInformation/Pages/minorityPopulations.aspx. Accessed 31 July 2013.
  3. 3.
    Ortiz AP, Colon-Lopez V, Girona-Lozada G, et al. Report of the 2012 Capacity building for HIV-HPV clinical trials recruitment among minority underserved populations of Hispanic origin in Puerto Rico. P R Health Sci J. 2012;31(3):185–7.PubMedCentralPubMedGoogle Scholar
  4. 4.
    Gifford AL, Cunningham WE, Heslin KC, et al. Participation in research and access to experimental treatments by HIV-infected patients. N Engl J Med. 2002;346(18):1373–82.PubMedCrossRefGoogle Scholar
  5. 5.
    Gwadz MV, Colon P, Ritchie AS, et al. Increasing and supporting the participation of persons of color living with HIV/AIDS in AIDS clinical trials. Curr HIV/AIDS Rep. 2010;7(4):194–200.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Menezes P, Eron JJ, Leone PA, Adimora AA, Wohl DA, Miller WC. Recruitment of HIV/AIDS treatment-naive patients to clinical trials in the highly active antiretroviral therapy era: influence of gender, sexual orientation and race. HIV Med. 2011;12(3):183–91.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Gwadz MV, Leonard NR, Cleland CM, et al. The effect of peer-driven intervention on rates of screening for AIDS clinical trials among African Americans and Hispanics. Am J Public Health. 2011;101(6):1096–102.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis. 2007;196(2):304–12.PubMedCrossRefGoogle Scholar
  9. 9.
    Wojna V, Skolasky RL, Hechavarria R, et al. Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment. J Neurovirol. 2006;12(5):356–64.PubMedCrossRefGoogle Scholar
  10. 10.
    McLaren PJ, Ripke S, Pelak K, et al. Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans. Hum Mol Genet. 2012;21(19):4334–47.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Bacon MC, von Wyl V, Alden C, et al. The Women’s Interagency HIV Study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol. 2005;12(9):1013–9.PubMedCentralPubMedGoogle Scholar
  12. 12.
    Corbie-Smith G, Odeneye E, Banks B, Shandor Miles M, Roman Isler M. Development of a multilevel intervention to increase HIV clinical trial participation among rural minorities. Health Educ Behav. 2013;40(3):274–85.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Freedberg KA, Sullivan L, Georgakis A, Savetsky J, Stone V, Samet JH. Improving participation in HIV clinical trials: impact of a brief intervention. HIV Clin Trials. 2001;2(3):205–12.PubMedCrossRefGoogle Scholar
  14. 14.
    Gwadz M, Cleland CM, Leonard NR, et al. Predictors of screening for AIDS clinical trials among African-Americans and Latino/Hispanics enrolled in an efficacious peer-driven intervention: uncovering socio-demographic, health, and substance use-related factors that promote or impede screening. AIDS Behav. 2013;17(2):801–12.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Gwadz MV, Leonard NR, Nakagawa A, et al. Gender differences in attitudes toward AIDS clinical trials among urban HIV-infected individuals from racial and ethnic minority backgrounds. AIDS Care. 2006;18(7):786–94.PubMedCrossRefGoogle Scholar
  16. 16.
    Russell SL, Katz RV, Wang MQ, et al. Belief in AIDS origin conspiracy theory and willingness to participate in biomedical research studies: findings in whites, blacks, and Hispanics in seven cities across two surveys. HIV Clin Trials. 2011;12(1):37–47.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Stone VE, Mauch MY, Steger K, Janas SF, Craven DE. Race, gender, drug use, and participation in AIDS clinical trials. Lessons from a municipal hospital cohort. J Gen Intern Med. 1997;12(3):150–7.PubMedCentralPubMedGoogle Scholar
  18. 18.
    Durant RW, Legedza AT, Marcantonio ER, Freeman MB, Landon BE. Different types of distrust in clinical research among Whites and African Americans. J Natl Med Assoc. 2011;103(2):123–30.PubMedCentralPubMedGoogle Scholar
  19. 19.
    Sullivan PS, McNaghten AD, Begley E, Hutchinson A, Cargill VA. Enrollment of racial/ethnic minorities and women with HIV in clinical research studies of HIV medicines. J Natl Med Assoc. 2007;99(3):242–50.PubMedCentralPubMedGoogle Scholar
  20. 20.
    Wendler D, Kington R, Madans J, et al. Are racial and ethnic minorities less willing to participate in health research? PLoS Med. 2006;3(2):e19.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Simoni JM, Huh D, Wilson IB, et al. Racial/ethnic disparities in ART adherence in the United States: findings from the MACH14 study. J Acquir Immune Defic Syndr. 2012;60(5):466–72.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Kyser M, Buchacz K, Bush TJ, et al. Factors associated with non-adherence to antiretroviral therapy in the SUN study. AIDS Care. 2011;23(5):601–11.PubMedCrossRefGoogle Scholar
  23. 23.
    Feinberg J, Saag M, Squires K, et al. Health-related quality of life in the gender, race, and clinical experience trial. AIDS Res Treat. 2011;2011:349165.PubMedCentralPubMedGoogle Scholar
  24. 24.
    Anastasi JK, Capili B, Kim GH, Chung A. Clinical trial recruitment and retention of a vulnerable population: HIV patients with chronic diarrhea. Gastroenterol Nurs. 2005;28(6):463–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Ickovics JR, Meisler AW. Adherence in AIDS clinical trials: a framework for clinical research and clinical care. J Clin Epidemiol. 1997;50(4):385–91.PubMedCrossRefGoogle Scholar
  26. 26.
    Freeman HP. Patient navigation: a community based strategy to reduce cancer disparities. J Urban Health. 2006;83(2):139–41.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Bradford JB, Coleman S, Cunningham W. HIV system navigation: an emerging model to improve HIV care access. AIDS Patient Care STDS. 2007;21(Suppl 1):S49–58.PubMedGoogle Scholar
  28. 28.
    Broadhead RS, Volkanevsky VL, Rydanova T, et al. Peer-driven HIV interventions for drug injectors in Russia: first year impact results of a field experiment. Intl J Drug Policy. 2006;17(5):379–92.CrossRefGoogle Scholar
  29. 29.
    Flay BR, Snyder F, Petraitis J. The theory of triadic influence. In: DiClimente RJ, Kegler MC, Crosby RA, editors. Emerging theories in health promotion practice and research. New York: Jossey-Bass; 2009.Google Scholar
  30. 30.
    Heckathorn DD. Respondent-driven sampling: a new approach to the study of hidden populations. Soc Probl. 1997;44(2):174–99.CrossRefGoogle Scholar
  31. 31.
    Miller W, Rollnick S. Motivational interviewing: preparing people for change. 2nd ed. New York: Guilford; 2002.Google Scholar
  32. 32.
    Leonard NR, Banfield A, Riedel M, et al. Description of an efficacious behavioral peer-driven intervention to reduce racial/ethnic disparities in AIDS clinical trials. Health Educ Res. 2013;28(4):574–90.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010;63(8):834–40.PubMedCrossRefGoogle Scholar
  34. 34.
    Engel S, Cleland CM. The experience of screening for HIV/AIDS medical studies among African-American/Black and Latino/Hispanic persons living with HIV/AIDS: a mixed-methods exploration. J AIDS Clin Res. 2013;4:223.CrossRefGoogle Scholar
  35. 35.
    Gandhi M, Ameli N, Bacchetti P, et al. Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols. AIDS. 2005;19(16):1885–96.PubMedCrossRefGoogle Scholar
  36. 36.
    Marshak A, Costantini G, Middleton S, et al. Screening for AIDS clinical trials in the project ACT cohort of racial/ethnic minorities and women in New York City: substantial interest but low eligibility. In: 4th International AIDS Society Conference, Sydney; 2007.Google Scholar
  37. 37.
    Hays RD, Spritzer KL, McCaffrey D, et al. The HIV cost & services utilization study (HCSUS) measures of health-related quality of life. Santa Monica: Rand; 1998.Google Scholar
  38. 38.
    Derogatis L, Melisaratos N. The brief symptom inventory: an introductory report. Psychol Med. 1983;13:595–605.PubMedCrossRefGoogle Scholar
  39. 39.
    Des Jarlais DC, Friedman SR, Novick DM, et al. HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987. JAMA. 1989;261(7):1008–112.PubMedCrossRefGoogle Scholar
  40. 40.
    Fleiss JL. Measuring nominal scale agreement among many raters. Psychol Bull. 1971;76:378–82.CrossRefGoogle Scholar
  41. 41.
    Albert A, Anderson A. On the existence of maximum likelihood estimates in logistic regression models. Biometrika. 1984;71:1–10.CrossRefGoogle Scholar
  42. 42.
    Firth D. Bias reduction of maximum likelihood estimates. Biometrika. 1993;80:27–38.CrossRefGoogle Scholar
  43. 43.
    Fay MP. Two-sided exact tests and matching confidence intervals for discrete data. R J. 2010;2(1):53–8.Google Scholar
  44. 44.
    Burger JM. The foot-in-the-door compliance procedure: a multiple-process analysis and review. Pers Soc Psychol Rev. 1999;3(4):303–25.PubMedCrossRefGoogle Scholar
  45. 45.
    Gwadz MV, Cylar K, Leonard NR, et al. An exploratory behavioral intervention trial to improve rates of screening for AIDS clinical trials among racial/ethnic minority and female persons living with HIV/AIDS. AIDS Behav. 2010;14(3):639–48.PubMedCrossRefGoogle Scholar
  46. 46.
    Penberthy L, Brown R, Wilson-Genderson M, Dahman B, Ginder G, Siminoff LA. Barriers to therapeutic clinical trials enrollment: differences between African-American and white cancer patients identified at the time of eligibility assessment. Clin Trials. 2012;9(6):788–97.PubMedCrossRefGoogle Scholar
  47. 47.
    Collins LM, Baker TB, Mermelstein RJ, et al. The multiphase optimization strategy for engineering effective tobacco use interventions. Ann Behav Med. 2011;41(2):208–26.PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    Murphy SA. An experimental design for the development of adaptive treatment strategies. Stat Med. 2005;24(10):1455–81.PubMedCrossRefGoogle Scholar
  49. 49.
    Lei H, Nahum-Shani I, Lynch K, Oslin D, Murphy S. A “SMART” design for building individualized treatment sequences. Ann Rev Clin Psychol. 2012;8:21–48.CrossRefGoogle Scholar
  50. 50.
    Hall HI, Frazier EL, Rhodes P, et al. Differences in human immunodeficiency virus care and treatment among subpopulations in the United States. JAMA Intern Med. 2013;173(14):1337–44.PubMedCrossRefGoogle Scholar
  51. 51.
    Torian LV, Wiewel EW. Continuity of HIV-related medical care, New York City, 2005–2009: do patients who initiate care stay in care? AIDS Patient Care STDS. 2011;25(2):79–88.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Marya Gwadz
    • 1
  • Charles M. Cleland
    • 1
  • Mindy Belkin
    • 1
  • Amanda Ritchie
    • 1
  • Noelle Leonard
    • 1
  • Marion Riedel
    • 2
  • Angela Banfield
    • 1
  • Pablo Colon
    • 1
  • Vanessa Elharrar
    • 3
  • Jonathan Kagan
    • 3
  • Donna Mildvan
    • 4
  • ACT2 Collaborative Research Team
  1. 1.Center for Drug Use and HIV ResearchNew York University College of NursingNew YorkUSA
  2. 2.School of Social WorkColumbia UniversityNew YorkUSA
  3. 3.National Institute of Allergy & Infectious Diseases National Institutes of HealthBethesdaUSA
  4. 4.Division of Infectious DiseasesMt. Sinai Beth Israel Medical CenterNew YorkUSA

Personalised recommendations